KR101160385B1 - 페길화된 Ａβ ＦＡＢ - Google Patents

페길화된 Ａβ ＦＡＢ Download PDF

Info

Publication number
KR101160385B1
KR101160385B1 KR1020097015076A KR20097015076A KR101160385B1 KR 101160385 B1 KR101160385 B1 KR 101160385B1 KR 1020097015076 A KR1020097015076 A KR 1020097015076A KR 20097015076 A KR20097015076 A KR 20097015076A KR 101160385 B1 KR101160385 B1 KR 101160385B1
Authority
KR
South Korea
Prior art keywords
antibody
fab
peg
seq
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097015076A
Other languages
English (en)
Korean (ko)
Other versions
KR20090101941A (ko
Inventor
켈리 레니 베일스
토마스 프랭크 부몰
치-킨 챠우
로날드 브래들리 데마토스
라이언 존 한센
움마 쿠치보틀라
지롱 류
피터 콜론 맥도넬
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39332186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101160385(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20090101941A publication Critical patent/KR20090101941A/ko
Application granted granted Critical
Publication of KR101160385B1 publication Critical patent/KR101160385B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097015076A 2007-01-18 2008-01-09 페길화된 Ａβ ＦＡＢ Expired - Fee Related KR101160385B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88543907P 2007-01-18 2007-01-18
US60/885,439 2007-01-18
PCT/US2008/050554 WO2008088983A1 (en) 2007-01-18 2008-01-09 PEGYLATED Aβ FAB

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127003094A Division KR101414847B1 (ko) 2007-01-18 2008-01-09 페길화된 Ａβ ＦＡＢ

Publications (2)

Publication Number Publication Date
KR20090101941A KR20090101941A (ko) 2009-09-29
KR101160385B1 true KR101160385B1 (ko) 2012-07-10

Family

ID=39332186

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097015076A Expired - Fee Related KR101160385B1 (ko) 2007-01-18 2008-01-09 페길화된 Ａβ ＦＡＢ
KR1020127003094A Expired - Fee Related KR101414847B1 (ko) 2007-01-18 2008-01-09 페길화된 Ａβ ＦＡＢ

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127003094A Expired - Fee Related KR101414847B1 (ko) 2007-01-18 2008-01-09 페길화된 Ａβ ＦＡＢ

Country Status (26)

Country Link
US (1) US8066999B2 (https=)
EP (2) EP2842967B1 (https=)
JP (2) JP5307030B2 (https=)
KR (2) KR101160385B1 (https=)
CN (2) CN103479998B (https=)
AR (1) AR064944A1 (https=)
AU (1) AU2008206555B2 (https=)
BR (1) BRPI0806715A2 (https=)
CA (1) CA2675847C (https=)
CL (1) CL2008000121A1 (https=)
CY (2) CY1116157T1 (https=)
DK (1) DK2121754T3 (https=)
EA (1) EA020979B1 (https=)
ES (2) ES2535641T3 (https=)
HR (2) HRP20150237T1 (https=)
IL (2) IL199838A (https=)
LT (1) LT2842967T (https=)
MX (1) MX2009007691A (https=)
PE (1) PE20081634A1 (https=)
PL (1) PL2121754T3 (https=)
PT (2) PT2121754E (https=)
RS (1) RS53948B1 (https=)
SI (2) SI2842967T1 (https=)
TW (1) TW200836763A (https=)
UA (1) UA95996C2 (https=)
WO (1) WO2008088983A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010014062A (es) 2008-06-20 2011-02-22 Novartis Ag Metodos para identificar regiones de enlace a macromoleculas y con tendencia a la agregacion en proteinas y usos de las mismas.
KR101784231B1 (ko) 2008-06-20 2017-11-08 노파르티스 아게 응집이 감소된 면역글로불린
CA2763935A1 (en) * 2009-06-04 2010-12-09 Novartis Ag Methods for identification of sites for igg conjugation
UY33253A (es) 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
US10431325B2 (en) 2012-08-03 2019-10-01 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
WO2015036553A1 (en) * 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
KR20150133576A (ko) 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
EP3496750A2 (en) 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
WO2019134039A1 (en) * 2018-01-04 2019-07-11 Septa Therapeutics, Inc. Septapeptides associated with neurodegeneracy
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071408A2 (en) * 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en) 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
JPH09511492A (ja) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
US5668651A (en) * 1994-03-18 1997-09-16 Sharp Kabushiki Kaisha Polymer-wall LCD having liquid crystal molecules having a plane-symmetrical bend orientation
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6413940B1 (en) 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6227999B1 (en) 1997-07-09 2001-05-08 Transmisiones Tsp, S.A. De C.V. Method and apparatus for operating a clutch in an automated mechanical transmission
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
US6114113A (en) 1997-08-11 2000-09-05 Chiron Corporation High efficiency genetic modification method
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
DE69942274D1 (de) 1998-05-21 2010-06-02 Univ Tennessee Res Foundation Methoden zur amyloidentfernung mit anti-amyloid-antikörper
WO2000077178A1 (en) 1999-06-16 2000-12-21 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
ATE283285T1 (de) 1999-08-04 2004-12-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
JP5153986B2 (ja) 2000-09-06 2013-02-27 アベンティス・ファーマ・ソシエテ・アノニム アミロイドーシスと関連する疾患のための方法及び組成物
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CA2457145C (en) 2001-08-17 2010-12-21 Washington University Assay method for alzheimer's disease
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
US20060073149A1 (en) 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
EP1429805A4 (en) 2001-08-17 2005-09-21 Lilly Co Eli USE OF ANTIBODIES WITH HIGH AFFINITY FOR A $ G (B) PEPTIDE IN THE TREATMENT OF DISEASES AND DISEASES RELATED TO A $ G (B)
US7166478B2 (en) 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
AU2003223474B2 (en) 2002-04-25 2008-09-04 Eli Lilly And Company Method for treating anxiety and mood disorders in older subjects
WO2004060965A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
CN1845938B (zh) * 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
EP1838349A1 (en) * 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071408A2 (en) * 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease

Also Published As

Publication number Publication date
MX2009007691A (es) 2009-07-29
WO2008088983A1 (en) 2008-07-24
JP5782479B2 (ja) 2015-09-24
IL230876A (en) 2016-06-30
EP2121754A1 (en) 2009-11-25
IL199838A0 (en) 2010-04-15
CY1116157T1 (el) 2017-02-08
EP2842967A1 (en) 2015-03-04
IL199838A (en) 2014-03-31
CL2008000121A1 (es) 2008-07-25
EP2121754B1 (en) 2015-02-11
AU2008206555B2 (en) 2013-07-04
JP2013241420A (ja) 2013-12-05
ES2615454T3 (es) 2017-06-07
PT2842967T (pt) 2017-01-13
SI2121754T1 (sl) 2015-03-31
KR20140015123A (ko) 2014-02-06
JP2010522141A (ja) 2010-07-01
CY1118554T1 (el) 2017-07-12
AU2008206555A1 (en) 2008-07-24
CN101981053B (zh) 2013-11-13
KR101414847B1 (ko) 2014-07-03
CA2675847C (en) 2014-12-30
CA2675847A1 (en) 2008-07-24
PE20081634A1 (es) 2008-11-22
RS53948B1 (sr) 2015-08-31
DK2121754T3 (en) 2015-02-23
EP2842967B1 (en) 2016-11-30
JP5307030B2 (ja) 2013-10-02
HK1190623A1 (zh) 2014-07-11
BRPI0806715A2 (pt) 2011-09-13
HRP20150237T1 (hr) 2015-04-10
SI2842967T1 (sl) 2017-01-31
TW200836763A (en) 2008-09-16
CN101981053A (zh) 2011-02-23
CN103479998A (zh) 2014-01-01
KR20090101941A (ko) 2009-09-29
EA020979B1 (ru) 2015-03-31
HRP20161677T1 (hr) 2017-01-27
US20100015155A1 (en) 2010-01-21
PL2121754T3 (pl) 2015-07-31
AR064944A1 (es) 2009-05-06
US8066999B2 (en) 2011-11-29
UA95996C2 (ru) 2011-09-26
PT2121754E (pt) 2015-05-11
CN103479998B (zh) 2015-11-18
IL230876A0 (en) 2014-03-31
LT2842967T (lt) 2017-02-27
ES2535641T3 (es) 2015-05-13
EA200970694A1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
KR101160385B1 (ko) 페길화된 Ａβ ＦＡＢ
EP1596809B1 (en) Abeta binding molecules
ES2818074T3 (es) Agente de unión a IL-17A y sus usos
KR20120098783A (ko) 인간 ｉｌ-２２ｒａ에 대한 인간화된 항체
CN117769434A (zh) 与C1s结合的抗体和其用途
MX2014007681A (es) Nuevo anticuerpo ctgf antihumano.
CA2745618C (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
AU2013231065B2 (en) Pegylated Aß Fab
HK1190623B (en) PEGYLATED Aβ FAB
BR112016009948B1 (pt) Agente de ligação à il-17a, seus usos, vetor, e composição farmacêutica
HK1158977B (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170621

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170621